Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 2/20 | 0.73 |
| ▸ | SELL | P14151 | 1/20 | 0.73 |
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.62 |
| ▸ | SELE | P16581 | 5/20 | 0.61 |
| ▸ | MAG | P20916 | 6/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29372449 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL13195877 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL13978771 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29389517 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29448496 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29391699 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29407985 | 0.99 | SELP (0.71) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29466129 | 0.98 | SELP (0.70) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29466139 | 0.98 | SELP (0.70) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL31010809 | 0.96 | SELP (0.71) | SELPSELLSIGLEC7SELEMAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119540713-A | Controllable bolt defect generation method based on visual angle and attribute guidance | 华北电力大学（保定） | 2025-02-28 | — | — | CN | claimed |
| EP-3775909-B1 | MEANS AND METHODS FOR GLYCOPROFILING OF A PROTEIN | GLYCANOSTICS S R O (SK) | 2023-05-10 | — | — | EP | claimed |
| US-20260139028-A1 | P-SELECTIN MUTANTS AND MODULATION OF INTEGRIN-MEDIATED SIGNALING | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260109950-A1 | COMPOSITIONS AND METHODS FOR PRODUCTION OF EXOFUCOSYLATED CELLS FOR CLINICAL APPLICATIONS | THE BRIGHAM AND WOMENS HOSPITAL (US) | 2026-04-23 | — | — | US | disclosed |
| US-12605469-B2 | Tumor specific antibody conjugates and uses therefor | THE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE (US) | 2026-04-21 | — | — | US | disclosed |
| US-12552873-B2 | Anti-PSGL-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof | VERSEAU THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20250375532-A1 | DUAL AFFINITY NANOPARTICLES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250361318-A1 | IMPROVED GLYCAN-DEPENDENT IMMUNOTHERAPEUTIC BI-SPECIFIC PROTEINS WITH LONGER HALF-LIFE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-11-27 | — | — | US | disclosed |
| WO-2025226744-A1 | SENESCENT CELL TARGETING T CELL RESPONSES BY EX VIVO GENERATED ANTIGEN PRESENTING CELLS | IMMORTA BIO, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-12447215-B2 | Nanoparticle probes and methods of making and use thereof | LEE PAUL C (US) | 2025-10-21 | — | — | US | disclosed |
| US-12331311-B2 | Protein modification of living cells using sortase | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2025-06-17 | — | — | US | disclosed |
| EP-3601548-B1 | RECOMBINANT GLYCOPROTEINS WITH REDUCED ANTENNARY FUCOSYLATION | CEVEC PHARMACEUTICALS GMBH (DE) | 2022-05-04 | — | — | EP | disclosed |
| EP-3990476-A1 | FLT3L-FC FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3980463-A1 | ANTI-PSGL-1 COMPOSITIONS AND METHODS FOR MODULATING MYELOID CELL INFLAMMATORY PHENOTYPES AND USES THEREOF | Verseau Therapeutics, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| US-20220096546-A1 | Modified Cell Expansion and Uses Thereof | INNOVATIVE CELLULAR THERAPEUTICS HOLDINGS, LTD. (KY) | 2022-03-31 | — | — | US | disclosed |
| CN-114245807-A | FLT3L-FC fusion proteins and methods of use | 吉利德科学公司 | 2022-03-25 | — | — | CN | disclosed |
| EP-3963333-A1 | METHOD FOR PERITONEAL METASTATIC CELL DETECTION AND ISOLATION THEREOF | The University of Hong Kong (CN) | 2022-03-09 | — | — | EP | disclosed |
| CN-114158275-A | Method for detecting and separating peritoneal metastatic cells | 香港大学 | 2022-03-08 | — | — | CN | disclosed |
| US-20220062442-A1 | NANOPARTICLE PROBES AND METHODS OF MAKING AND USE THEREOF | LEE PAUL C (US) | 2022-03-03 | — | — | US | disclosed |
| US-20220049021-A1 | FLT3L-Fc FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139028-A1 | P-SELECTIN MUTANTS AND MODULATION OF INTEGRIN-MEDIATED SIGNALING | SELP, SELPLG, SELL | SELP 1/4885SELL 3/4885SIGLEC7 34/4885 |
| US-12331311-B2 | Protein modification of living cells using sortase | SORT1, ENGASE, SIGLEC7 | SELP 126/4885SELL 229/4885SIGLEC7 3/4885 |
| US-20260109950-A1 | COMPOSITIONS AND METHODS FOR PRODUCTION OF EXOFUCOSYLATED CELLS FOR CLINICAL APPLICATIONS | FUCA2, FUCA1, ST6GAL1 | SELP 102/4885SELL 46/4885SIGLEC7 26/4885 |
| US-12552873-B2 | Anti-PSGL-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof | CD209, CSF3R, CHI3L1 | SELP 143/4885SELL 43/4885SIGLEC7 62/4885 |
| US-12605469-B2 | Tumor specific antibody conjugates and uses therefor | MUC1, CD47, CD44 | SELP 631/4885SELL 61/4885SIGLEC7 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.